<DOC>
	<DOCNO>NCT02705755</DOCNO>
	<brief_summary>This multiple-center , randomize , 2-part , single- double-blind study conduct male female subject neurogenic orthostatic hypotension evaluate effect TD-9855 improving symptom orthostatic intolerance .</brief_summary>
	<brief_title>TD-9855 Phase 2 Neurogenic Orthostatic Hypotension ( nOH )</brief_title>
	<detailed_description />
	<mesh_term>Hypotension</mesh_term>
	<mesh_term>Hypotension , Orthostatic</mesh_term>
	<criteria>Diagnosed symptomatic orthostatic hypotension due Parkinson 's disease , multiple system atrophy , pure autonomic failure , ( i.e . neurogenic orthostatic hypotension ) At screening , subject must meet diagnostic criterion neurogenic orthostatic hypotension , demonstrate â‰¥ 30 mm Hg drop systolic blood pressure ( SBP ) within 5 minute stand Impaired autonomic reflex , determine absence BP overshoot phase IV Valsalva maneuver Systemic illnesses know produce autonomic neuropathy , include limited diabetes mellitus , amyloidosis , monoclonal gammopathy unknown significance , autoimmune neuropathy . Concomitant use vasoconstricting agent purpose increase BP ephedrine , dihydroergotamine , midodrine must stop take drug least 2 day five halflives ( whichever longer ) prior dose Day 1 throughout duration study . Concomitant use antihypertensive medication treatment essential hypertension unrelated autonomic dysfunction . Known suspected alcohol substance abuse within past 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>